The KRAS Opportunity: A Tale of Two Biotechs The FDA's approval of Revolution Medicines' Rasonque has sent shockwaves through the biotechnology industry.
This once daily oral tablet marks a significant milestone in the treatment of metastatic pancreatic adenocarcinoma, offering new hope to patients who have long been underserved by targeted therapies.
Incyte Corporation (INCY) and Revolution Medicines (RVMD) are two companies vying for position in the KRAS inhibitor market.